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Summary The inherent or acquired (induced) resistance of certain tumours to cytotoxic drug therapy is a major clinical problem. There
are many categories of cytotoxic agent: the antimetabolites, e.g. methotrexate (MTX), N-phosphonacetyl-L-aspartate (PALA), 5-fluorouracil
(5-FU), 6-mercaptopurine (6-TG), hydroxyurea (HU) and 1-pB-D- arabinofuranosylcytosine (AraC); the alkylating agents, e.g. the nitrogen
mustards and nitrosoureas; the antibiotics, e.g. doxorubicin and mitomycin C; the plant alkaloids, e.g. vincristine and vinblastine; and
miscellaneous compounds, such as cisplatin. There are also many mechanisms of drug resistance elucidated principally from in vitro studies.
These include mutation of target genes, amplification of target and mutated genes, differences in repair capacity, altered drug transport and
differences in nucleoside and nucleobase salvage pathways (Fox et al, 1991). The aim of the present review is to evaluate in detail the
mechanisms of response of both normal and tumour cells to three chemotherapeutic antimetabolites, MTX, PALA and 5-FU, which are
routinely used in the clinic either alone or in combination to treat some of the commonest solid tumours, e.g. breast, colon, gastric and head
and neck. The normal and tumour cell response to these agents will be discussed in relation to the operation of the known alternative 'salvage
pathways' of DNA synthesis and current theories of DNA damage response.
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BACKGROUND
The majority of anticancer drugs mediate their cytotoxicity either
by inhibiting DNA synthesis or by damaging the DNA template
(Fox et al, 1991). The chemotherapeutic antimetabolites are used
to target 'key' enzymes in the pathways of de novo purine and
pyrimidine biosynthesis (Weber, 1983). The original hypothesis
was that the rapidly proliferating tumour cells might be more
sensitive to their cytotoxic action than the normal cells.
Paradoxically, however, both acquired resistance and inherent
resistance to cytotoxic drugs, and chemotherapeutic antimetabo-
lites in particular, are now accepted to be more common features
of tumour cells than normal cells (Wright et al, 1990; Kinsella and
Haran, 1991; Lucke-Huhle, 1994). The evidence for this comes
from the in vitro observations that tumour cells more readily
amplify their DNA than normal cells in response to chemothera-
peutic agents (Wright et al, 1990 and refs therein). In vitro studies
have also shown that tumour cells are inherently more resistant to
the cytotoxic effects of the chemotherapeutic antimetabolites
because ofprogression- linked changes in their pathways ofpurine
and pyrimidine biosynthesis (Weber, 1983; Kinsella and Haran,
1991; Weber and Prajda, 1994).
Received24 September 1996
Revised24 September 1996
Accepted 16 October 1996
Correspondence to: AR Kinsella
FH2
Dihydrofolate Methotrexate
reductase
4 H4
5, 10OCH2 FH4 100CHOFH4
Pyrimidine DNA Purine
Synthesis L J Synthesis
Figure 1 Mechanism of action of MTX by depletion of reduced folate pools
MECHANISMS OF ACTION OF MTX, PALA
AND 5-FU
All three of the chemotherapeutic antimetabolites MTX, PALA
and 5-FU inhibit key steps in the pathways for the generation of
the purine (dATP, dGTP) and pyrimidine (dTTP, dCTP)
nucleotides, which are the precursors ofDNA synthesis. In simple
terms, inhibition of these pathways leads to a shortage of the
building blocks for DNA, inhibition of DNA synthesis and,
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Figure 2 Schematic representation of the de novo and salvage pathways of
pyrimidine biosynthesis adopted from Weber (1983)
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depending on the drug and the cell type, the rapid or eventual
induction ofDNA strand breaks. The detailed mechanisms oftheir
action are outlined below.
Methotrexate
Methotrexate is an antifolate and a specific inhibitor ofthe enzyme
dihydrofolate reductase (DHFR), which plays a critical role in
intracellular folate metabolism (Chabner and Collins, 1990). It
exerts its antineoplastic effects by limiting the synthesis of the
reduced folates that act as co-factors for several 'key' enzyme reac-
tions of purine and pyrimidine nucleotide synthesis (Figure 1).
Reduced folates are essential forfirstly the conversion ofdeoxyuri-
dine monophosphate (dUMP) to deoxythymidine monophosphate
(dTMP), a key step in pyrimidine nucleotide synthesis (Figure 2)
which is catalysed by the enzyme thymidylate synthase (TS), and
secondly for purine synthesis (Figure 1) (Erlichman, 1992). Thus,
MTX depletes three nucleotide pools, namely guanine triphosphate
(GTP), adenine triphosphate (ATP) and thymidine triphosphate
(TTP). In addition, it is thought that the formation of MTX and
dihydrofolate polyglutamates results in further inhibition of the
same folate-dependent enzymes (Allegra etal, 1986, 1987; Allegra,
1990). This reduction in the pools of available pyrimidine and
purine nucleotides and the impairment of the ability to repair sites
of DNA damage eventually results in MTX-induced single- and
double-strand breaks (Lorico et al, 1988; Borchers et al, 1990). In
addition, the intracellular build-up of dUMP because ofTS inhibi-
tion and negative feedback inhibition by dCMP deaminase results
in the incorporation of dUTP into DNA (Figure 2), resulting in
chain elongation and inhibition of DNA synthesis. Excision repair
of the DNA containing these dUTP moieties may lead to further
DNA strand breaks and fragmentation (Borchers et al, 1990).
Resistance to MTX is conferred on cells by a variety of mecha-
nisms which include: alteration of MTX transport, resulting in a
non-inhibitory cell concentration; mutation of the DHFR gene,
resulting in a protein product with a reduced binding affinity for
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Figure 3 The metabolic activation of 5-fluorouracil produces the metabolites
5-FUTP and 5-FdUMP which can incorporate into RNA or DNA or block
thymidylate synthetase activity
MTX; and overproduction of the DHFR gene product as a conse-
quence of gene amplification (Schimke, 1984a). Treatment with
anti-cancer drugs themselves can enhance the emergence of drug
resistance. In the case of MTX, pretreatment of mouse cells with
hydroxyurea (Brown et al, 1983) or UV irradiation (Tlsty et al,
1984) or in hamster cells transient hypoxia (Rice et al, 1986) or
pretreatment with MTX itself (Tlsty et al, 1982) or AraC (Goz et
al, 1989) enhanced the appearance of MTX-resistant clones in
clonogenic assays. Molecular analysis of the basis for these
changes showed all three mechanisms (altered transport, altered
affinity and gene amplification) to be increased (Flintoff et al,
1976; Brown et al, 1983; Tlsty et al, 1984). Administration of the
tumour promoter TPA was shown to enhance the emergence of
MTX resistance in mouse but not in hamster cells in the absence of
gene amplification (Bojan et al, 1983). This was later attributed to
the influence of the tumour promoter TPA on the cell cycle
(Szallasi et al, 1988). While in a series of human fibroblast cell
lines differences in inherent resistance, in the absence of gene
amplification, have been attributed to differences in salvage
pathway involvement (Kinsella and Haran, 1991). Salvage path-
ways circumvent the normal de novo pathways of nucleotide
biosynthesis by using nucleosides in the surrounding cellular
environment as substrates for their enzymes in the process of
nucleotide synthesis.
PALA
The chemotherapeutic antimetabolite PALA was specifically
synthesized to be a stable inhibitor of the enzyme aspartate tran-
scarbamylase, which catalyses the second step ofde novo pyrimi-
dine biosynthesis (Figure 2) (Collins and Stark, 1971). It is a
potent inhibitor of de novo pyrimidine nucleotide synthesis
(Swyryd et al, 1974; Yoshia et al, 1974; Martin et al, 1983) and
specifically causes decreases in the UTP and CTP pools (Wahl et
al, 1979; Moyer et al, 1982). Inhibition of DNA synthesis and the
secondary induction of DNA strand breaks is the primary limita-
tion on replication for cells grown in low concentrations ofPALA.
However, inhibition of RNA synthesis may become an important
factor during prolonged exposure to high concentrations (Moyer
et al, 1982). The molecular basis for resistance to PALA is
considered almost exclusively to be amplification of the multi-
functional CAD gene, the products ofwhich catalyse the first three
reactions ofde novo pyrimidine synthesis (Wahl et al, 1979; Stark
and Wahl, 1984; Goz et al, 1989). However, the enhanced inherent
resistance of premalignant and malignant human fibroblasts to a
single exposure of PALA has been shown to be a consequence
ofthe efficacy ofthe salvage pathways ofpyrimidine biosynthesis
in the absence of any amplification of the target gene (Kinsella
and Haran, 1991).
5-FU
5-FU was specifically synthesized for the clinic (Heidelberger et
al, 1957; 1983) to resemble the pyrimidine bases uracil and
thymine. The drug is rapidly taken up by cells and is rapidly
metabolized by a number of enzymes along several pathways
(Sotos et al, 1994 and refs therein) (Figure 3) to produce two active
metabolites, i.e. 5-FUTP, which may be incorporated directly into
RNA, and 5-dFUMP. 5-dFUMP in the presence ofreduced folates
inhibits TS activity and depletes dTTP, a necessary precursor
of DNA synthesis (Mandel, 1969; Sommer and Santi, 1974).
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Alternatively, it may be phosphorylated to the triphosphate and 5-
FdUTP incorporated directly into DNA, inhibiting chain elonga-
tion and altering DNA stability, resulting in the production of
single-strand breaks and DNA fragmentation (Cheng and
Nakayama, 1983). The fluoropyrimidines may also induce DNA
strand breaks without being incorporated into DNA, possibly
through the inhibition of DNA repair as a consequence of dTTP
depletion (Yoshioka et al, 1987). The relative contribution ofeach
of these mechanisms remains unclear and may depend on the
specific patterns of intracellular 5-FU metabolism associated with
different normal and tumour cell types.
Resistance to 5-FU is achieved through a variety of mecha-
nisms, including deletion of the key enzyme required for its acti-
vation, the increased activity of a catabolic enzyme, a lack of
reduced folate substrate and an alteration in TS activity through
gene amplification, over-expression or mutation (Jastreboff et al,
1983; Berger et al, 1985; Barbour et al, 1990; Chu et al, 1991).
There is also evidence ofsalvage pathway involvement (Grem and
Fischer, 1989).
ACQUIRED RESISTANCE
Resistance toantineoplastic drugs can develop through avariety of
mechanisms as cited at the beginning of this review and, more
specifically, above for the chemotherapeutic antimetabolites. One
of the mechanisms of acquired drug resistance commonly associ-
ated with the chemotherapeutic antimetabolites MTX, PALA and
5-FU is the amplification ofthe genescoding for the specific target
enzymes ofpurine and pyrimidine biosynthesis.
Gene amplification, the process which gives rise to multiple
copies of a single gene within a single cell, is the result ofstepwise
drug selection and results in overproduction of a normal protein
and eventually high levels of resistance (Schimke, 1984b). It is
now recognized that the propensity for gene amplification corre-
lates for the most part but not exclusively with the transformed
phenotype (Cillo et al, 1989; Lucke-Huhle, 1989; Otto et al, 1989;
Perry et al, 1992). Recently, permissivity for MTX-induced gene
amplification was shown to correlate with the metastatic pheno-
type (Lucke-Huhle, 1994). Oncogenes, e.g. myc and ras are
frequently amplified in tumour cell lines (Schwab and Amler,
1990; Brennan et al, 1991), and immortalized and tumour cell
lines readily develop resistance to MTX, PALA and another
antimetabolite hydroxyurea (HU) (Figure 2) by amplification of
the corresponding target genes (Stark and Wahl, 1984; Stark,
1986). Mutant cell lines withhigh rates ofamplification and which
are doubly resistant to both MTX and PALA have been selected
from rodent cells (Giulotto et al, 1987). These cell lines were said
to have an 'amplificator phenotype,' i.e. to be permissive for
amplification. What is not certain is whether gene amplification is
a manifestation of genetic instability or the driving force for
genetic instability (Stark et al, 1989; Windle and Wahl, 1992;
Stark, 1993; Ishizaka et al, 1995) and this remains difficult to
assess because the drugs themselves, e.g. MTX, PALA and 5-FU,
generate DNA damage and genetic instability.
However, we do know that normal rodent and human cells in
vitro fail to develop resistance to drugs like MTX, PALA and 5-FU
and fail to amplify the genes normally targeted by these drugs.
Support for this comes from the fact that amplification has not been
reported in the normal cells ofpatients undergoing prolonged cyto-
toxic drug therapy (Wright et al, 1990). Normal cells do not exhibit
the genetic instability exhibited by the immortalized or tumour
cells. Recent mechanistic studies suggest that the tumour-
suppressorgenep53 isrequiredtomaintainthenon-permissive state
with respect to gene amplification (Livingstone et al, 1992; Yin et
al, 1992; Lucke-Huhle, 1994). As DNA damage is likely to be the
first step in the process leading to gene amplification, it is under-
standable why cells with an intact wild-type (WT) p53 pathway do
not produce resistant subclones at experimentally measurable rates
(Tlsty etal, 1989; Tlsty, 1990; Wrightetal, 1990). In contrastloss of
WT p53 function allows immortalized non-tumorigenic and
primary fibroblasts to cycle in the presence of chromosome breaks
and undergo gene amplification at experimentally measurable rates
(Kastan et al, 1991; Livingstone et al, 1992; Yin et al, 1992).
Titration experiments indicate that the p53-dependent arrest mecha-
nism in normal human fibroblasts can be activated by very
few double-strandbreaks and thatjustone may be sufficient(Huang
etal, 1996).
Thus the process is complicated. It is not simply a case of gene
amplification being facilitatedby a more aggressively transformed
phenotype. We now know that pretreatment with otherdrugs facil-
itates increased resistance and may be a feature of the ability of
these agents to inhibit DNA synthesis or induce DNA damage
(Stark et al, 1989). One can speculate that repeated exposure to
chemotherapeutic antimetabolites either alone or in combination
creates the conditions for amplification of the target genes in
tumour cells that are perhaps already primed for amplification by
virtue oftheir genetic instability (Schimke et al, 1986; Stark et al,
1989). This may in turn reflect the genetic status ofthe target cell.
Thus, tumour cells, unlike their normal counterparts, have proper-
ties that facilitate the acquisition of resistance to repeated expo-
sures ofchemotherapeutic antimetabolites.
INHERENT RESISTANCE
Acquired resistance after prolonged and repeated exposure to a
chemotherapeutic agent is only one mechanism of resistance.
Many tumours seem to be inherently resistant to the chemothera-
peutic agent used. An example ofthis is 5-FU, which is the main-
stay of therapy for advanced colorectal and gastric malignancies
(Sotos et al, 1994). The efficacy of 5-FU is limited by the lack of
response in a substantial percentage ofthepatients who receive the
drug. It only achieves a response rate of 10-20 per cent when used
as a single agent (Grem and Fischer, 1989; Sotos et al, 1994).
There have been many attempts at biomodulation of 5-FU in an
effort to improve its efficacy. These have included the use of
MTX, PALA, cisplatin, alpha interferon and leucovorin (folinic
acid) (Sotos et al, 1994). Of these, only leucovorin has proved to
be clinically useful. The rationale forthe combination of5-FU and
folinic acid was based on biochemical and cell culture studies
using a number of cell lines (Ullman et al, 1978; Waxman et al,
1978; Evans et al, 1981; Houghton et al, 1981). These studies
demonstrated that an excess of intracellular reduced folates was
necessary for optimal inhibition of thymidylate synthase and for
an increased cytotoxic effect of fluorinated pyrimidines. This
observation led to the first clinical trial of5-FU and folinic acidby
Manchover et al (1982). Subsequently several randomized trials of
5-FU + folinic acid vs 5-FU alone were performed in advanced
colorectal carcinoma patients. In 1992, such patients were
subjected to meta-analysis which showed a statistically significant
advantage in terms of response rate, i.e. 23% vs 11% (for 5-FU +
folinic acid vs 5-FU alone) (Advanced Colorectal Meta-analysis
Project). At present, 5-FU modulated by folinic acid remains the
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Figure 4 The intrinsic sensitivities of the normal KMS, immortalized KMST
and tumorigenic KN-NM cell lines to (A) MTX, (B) PALA and (C) 5-FU in the
presence and absence of the nucleoside transport inhibitordipyridamole
most effective available treatment for advanced colorectal cancer.
However, it seems that certain colorectal malignancies have an
inherent resistance to this agent.
Over the years, it has become increasingly obvious thatdrugs do
not only need to be targeted against the key enzymes of the de
novo pathways of purine and pyrimidine biosynthesis but also
against the activities of the 'salvage pathways' of purine and
pyrimidine synthesis, which can circumvent the inhibition of the
pathways of de novo synthesis (Weber, 1983; Kinsella and Haran,
1991; Fox et al, 1991; Weber and Prajda, 1994). It has long been
recognized from in vitro studies that inhibition of de novo
synthesis leads to the increased accumulation of substrates of the
salvage pathways (Plagemann et al, 1978; Cadman and Benz,
1980). Studies by Weber and co-workers have demonstrated over a
number of years that cancer cells in the logarithmic phase of
growth and hepatomas of different growth rates show a marked
rise in the activities of both the de novo and salvage enzymes of
purine and pyrimidine synthesis. More recently, studies in rat
hepatoma, rat sarcoma and human colorectal cancer have shown
the activities of the enzymes of the salvage pathways to be higher
than the rate-limiting enzymes ofde novo synthesis (Natsumeda et
al, 1989). Camici et al (1990) reported higher levels of the purine
salvage pathway enzyme hypoxanthine guanine phosphoribosyl
transferase (HGPRT) in tumours than in peritumour tissues. This
highlighted the role that salvage pathways might play in circum-
venting the action ofthe antimetabolites in a therapeutic setting.
Certainly there are a spectrum of reports in vitro of augmenta-
tion of the effects of MTX by inhibition of thymidine salvage
using the nucleoside transport inhibitor dipyridamole (Marz et al,
1977; Cabral et al, 1984; Nelson and Drake, 1984; van Mouwerik
et al, 1987). Dipyridamole is a reversible competitive inhibitor of
nucleoside transport. The ability ofdipyridamole to prevent nucle-
oside salvage in general has been exploited in human cell lines in
in vitro studies of both MTX and PALA cytotoxicity (Chan and
Howell, 1985; Kennedy et al, 1986). Moreover, AraC enhance-
ment ofMTX and PALA resistance was blocked by the nucleoside
transport inhibitor dipyridamole (Goz and Jeffs, 1994). Previous
workby the authors (Kinsella and Haran, 1991) showed increasing
resistance to the chemotherapeutic antimetabolites MTX and
PALA paralleling progression towards tumorigenicity in a series
of isogenic human fibroblast cell lines. An increase in the sensi-
tivity of all the cell lines to both MTX and PALA was observed
when the experiments were performed in dialysed serum from
which essentially all the salvage pathway substrates had been
eliminated. This suggested an important role for the salvage path-
ways ofpurine and pyrimidine biosynthesis and their substrates in
the original resistance of these cell lines. This was confirmed by
the restoration of the resistance of the KN-NM tumorigenic cell
line to PALA by the addition ofuridine to the medium. Uridine is
the key nucleoside for PALA 'rescue' (Figure 2) in that both CTP
and TTP can be produced from it. This was the first comparative
study in isogenic cell lines and showed not only that salvage path-
ways were involved in resistance but also that there were very
clear differences in the levels of the salvage pathway activity
between normal and tumour cells.
Extension of these initial in vitro studies to include the nucleo-
side transport inhibitor dipyridamole and another chemothera-
peutic antimetabolite, 5-FU, provided an unexpected insight
into the possible operative mechanisms. As expected, from our
previous observations with MTX and PALA (Kinsella and Haran,
1991), the tumorigenic human fibroblast cell line KN-NM
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was more resistant than the immortalized cell line KMST from
which it was derived, which in turn was more resistant than the
normal cell line KMS to a single exposure of 5-FU in clonogenic
assays. Addition of dipyridamole increased the intrinsic sensitivi-
ties of all three cell lines to MTX and PALA (Figure 4A and B),
which was consistent with the earlier observations in dialysed
serum (Kinsella and Haran, 1991). The effects of dipyridamole on
PALA resistance were reversed by the addition of the salvage
pathway substrate uridine and on MTX resistance by the addition
of hypoxanthine and thymidine in combination (Pickard et al,
1995). However, addition of dipyridamole had no effect on the
resistance of any of the three cell lines to 5-FU (Figure 4C). This
suggested that, contrary to expectation, there was no salvage
pathway involvement in the increased resistance of the immortal-
ized (KMST) and tumorigenic (KN-NM) cell lines to 5-FU
(Figure 4C).
So, what is going on in these cells in response to 5-FU? Early
reports in the literature have shown 5-FU inhibition of TS to be
growth limiting in mouse sarcoma and mouse L cells and have
shown that this can be reversed by the addition of exogenous
thymidine (Madoc- Jones and Bruce, 1968; Evans et al, 1980).
This suggests that dipyridamole may be able to enhance 5-FU
cytotoxicity by inhibiting thymidine salvage in cells in which the
DNA-directed effects of 5-FU predominate. This has been
confirmed in human colon carcinoma cell lines in which inhibition
of TS has been shown to be growth limiting at relatively low
concentrations of 5-FU (Miller et al, 1987; Schwartz et al, 1987).
Obviously, in our study, no such effect of dipyridamole is opera-
tive. Dipyridamole has previously been shown to enhance 5-FU
induced cytotoxicity in a human colon carcinoma cell line (Grem
and Fischer, 1985), but this was shown not to be as a result of
depletion of the TTP pools and was unrelated to the availability of
exogenous thymidine. In fact, dUMP was shown to be the key
effector of cytotoxicity (Grem and Fischer, 1986). This lack of a
role for salvage pathway involvement is reasonably consistent
with the evidence from clinical studies.
Whether or not a thymidine salvage pathway contributes to clin-
ical resistance to 5-FU is difficult to determine with absolute
certainty. Several phase 1/11 trials have been performed using
dipyridamole in combination with 5-FU-based chemotherapy in an
attempt to address this question and in general the results suggest
that little if any benefit accrues from the addition of dipyridamole
(Tsavaris et al, 1990; Grem, 1992). This is in keeping with the clin-
ical observation that folinic acid potentiates the cytotoxicity of 5-
FU, suggesting that dUMP interaction with thymidylate synthase is
the major effector of 5-FU cytotoxicity, which would be consistent
with the early in vitro observations of Grem and Fischer (1986).
However, it is probable that none of the studies investigating 5-FU
+ dipyridamole achieved concentrations of dipyridamole in the
range known to biomodulate 5-FU in vitro in cell culture systems.
In one trial, dipyridamole and 5-FU were administered as a contin-
uous intravenous infusion over 72 h (Grem, 1992). At the
maximum-tolerated dose of dipyridamole, the steady state concen-
tration was of the order of 25 nm, some 20-fold lower than that
known to produce optimal biomodulation of 5-FU in the HCT116
colorectal carcinoma cell line. In addition, in this trial, dipyri-
damole caused an increase in the clearance of 5-FU, resulting in a
reduced steady-state plasma concentration and possibly reducing
the effectiveness ofthe drug. A further piece ofevidence is an early
study in which thymidine was actually combined with 5-FU (Vogel
et al, 1979). This was based on evidence that thymidine could
enhance the incorporation of 5-FU into RNA and that thymidine
could delay the breakdown of 5-FU by the hepatic enzyme dihy-
drouracil dehydrogenase and thus prolong the 5-FU plasma half-
life. In this trial, thymidine did not alter the effect of 5-FU. It
appears therefore that at clinically relevant doses neither dipyri-
damole nor thymidine affect resistance to 5-FU.
RESISTANCE TO 5-FU A FUNCTION OF DNA
DAMAGE RESPONSE
Recently, it has been postulated that the outcome ofdrug therapy is
determined by the response of a cell according to its phenotype
rather than by the nature of the primary drug target interaction
(Dive and Hickman, 1991). The hypothesis was that tumour cells
were resistant to the genetic programme for cell death and there-
fore the tumour cell population continued to expand and appeared
to be resistant to cytotoxic drugs. It is now known that the p53
gene product in its role as 'guardian of the genome' (Lane, 1992;
Levine et al, 1993), plays an important role in determining the
cellular response to DNA damage. Expression and stability of the
p53 gene product is induced in cells following exposure to DNA
damaging agents (Kastan et al, 1991) and leads either to cell cycle
arrest, which may facilitate DNA repair (Mcllwrath et al, 1994;
Nelson and Kastan, 1994), or cell death by apoptosis (Clarke et al,
1993; Lowe et al, 1993a, b), dependent on cell type.
In human fibroblast studies undertaken by the authors, immuno-
histochemical analysis (Hall and Lane, 1994) suggested that the
normal p53 function had been disrupted in the immortalized and
tumorigenic cell lines (Pickard et al, 1995). This led us to postulate
that the differences in the sensitivities of the cell lines to 5-FU
(Figure 4C) might be a consequence of differing cellular responses
to drug-induced damage. Measurement of5-FU-induced apoptosis
in the three cell lines showed the normal KMS cell line with
WTpS3 to apoptose at a lower level than its more resistant
immortalized and tumorigenic derivatives (Pickard et al, 1995).
Thus, the differences in resistance could not be explained on the
basis of differences in apoptosis between the cell lines. Detailed
cell cycle analysis and proliferation studies, however, showed that
the normal human fibroblast cell line ceased to proliferate in
response to increasing concentrations of 5-FU and entered a
permanent growth arrest at a 5-FU concentration as low as
1 X 10-5M. This was in contrast to the immortal and tumorigenic
cell lines that continued to proliferate at a 5-FU concentration of
I X 10-5M, apparently regardless of the drug insult. This suggested
that the G1 checkpoint had been lost in these cell lines. The loss of
p53 function may be an important factor in determining the
increased resistance of the immortalized and tumorigenic cell
lines to 5-FU.
IS THERE A ROLE FOR DNA DAMAGE
RESPONSE IN RESISTANCE TO MTX AND PALA?
Recent studies have identified increased levels of p53 protein that
coincide with the appearance ofstrand breaks induced by all three of
the antimetabolites MTX, PALA (Nelson and Kastan, 1994) and 5-
FU (Fritsche et al, 1993). However, the evidence ofa strong salvage
pathway involvement in the resistance to MTX and PALA allows
one to speculatethatthe salvagepathways may be operating to repair
and synthesize DNA to such adegree that the strand breaks expected
to occur in response to antimetabolite insult fail to materialize. For
example, in the case of the resistance of the human fibroblast cell
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lines to PALA (Figure 4B) (Pickard and Kinsella 1996), all the
substrates distal to the block (Figure 2) will have to be used.
Moreover, the nucleosides and bases in the surrounding environment
can be used by the salvage pathways to regenerate any depleted
pools. Any available thymidine will be converted to TTP and any
available uridine will be converted to CTP and TTP. Thus, the
nucleotides required for DNA synthesis and repair continue to be
provided, and so no strand breaks occur and no DNA damage
response pathway is initiated. With the addition ofdipyridamole and
the inhibition of nucleoside and nucleobase transport, the levels of
available uridine andthymidine for the salvage pathways are greatly
decreased and the availability of CTP and TTP is diminished. As a
result, DNA synthesis and repair are inhibited and DNA strand
breaks occur, eliciting a delayed DNA damage response in the pres-
ence ofnormal p53 in the KMS cell line and allowing the continued
proliferation ofthe KMST and KN-NM cell lines with theirdysfunc-
tionalp53. Ifwe look in detail atthe effectofdipyridamole(5 uM) on
the resistance ofthe three cell lines to PALA (Figure4B), we see that
dipyridamole increases the intrinsic sensitivities of both the immor-
talized (KMST) and the tumorigenic (KN-NM) cell lines so thatthey
are equally sensitive and increases the sensitivity of the already
sensitive normal (KMS) cell line. However, even in the presence of
dipyridamole, there is still a difference in resistance to PALA
between the normal and the more tumorigenic cell lines (Figure 4B).
Thus, the differing abilities ofthe cell lines to elicit a DNA damage
response explains the enhanced resistance of the KMST and KN-
NM cell lines to PALA comparedwith the KMS cellline, even in the
presence ofdipyridamole (Figure 4b). There are therefore two clear
components to the response ofthese cells to PALA.
The situation with MTX (Figure 4A) is more complicated but
one can speculate that the same principles apply (Pickard and
Kinsella, 1996). We know from the 5-FU data that the normal
KMS cell line responds to DNA damage. Thus, the differences in
the resistance oftheseparticular human fibroblast cell lines to both
MTX and PALA are clearly not only a function of differences in
the salvage pathways but also of differences in the abilities of the
cells to elicit a p53-dependent DNA damage response. In the case
of 5-FU (Figure 4C), one has to assume in the absence of an effect
of dipyridamole that the drug is mediating its effects via its direct
action on DNA (Parker and Cheng, 1990) and that, as stated previ-
ously, only the DNA damage response is important. No growth
arrest was observed in any of the cell lines at concentrations of
PALA up to and including 10 mm, except in the case ofthe normal
cell line in the presence ofdipyridamole.
Recently, however, in a different human fibroblast cell line
(Linke et al, 1996), UTP, GTP and CTP depletion following treat-
ment with PALA (or pyrazofurin) resulted in reversible
antimetabolite-induced growth arrest in the G, phase of the cell
cycle, which correlated with p53 induction in the absence of
apparent DNA damage. In the same fibroblast cell line, MTX and
5-FU treatment resulted in an early S phase arrest that could be
prevented by co-treatment with the salvage pathway substrate
thymidine. Thus, Linke et al (1996) speculated thatp53 might play
a role in the induction of a quiescent state in response to metabolite
depletion and senescence or permanent arrest, such as thatreported
by the authors in human fibroblasts in response to 5-FU (Pickard et
al, 1995) andby Di Leonardo et al (1994) in response to irradiation
in the presence of DNA damage. It is known that p21, a down-
stream effector of p53, increases reversibly in quiescent cells and
irreversibly in senescent cells (Noda et al, 1994). These studies and
those ofLi et al (1995) also provide evidence ofa link between p53
and the product ofretinoblastoma tumour-suppressor gene (RB) in
the resistance of certain cells to the chemotherapeutic antimetabo-
lites (Almasan et al, 1995; Li et al, 1995). RB codes for a nuclear
protein implicated in the transition from the GI to S phase of the
cell cycle. TheG, cyclin-dependent kinase (cdk) complexes, which
are inhibited by p21 a downstream effector of p53, phosphorylate
the RB protein (Harper et al, 1993; Dulic et al, 1994), allowing the
release ofthe transcriptional activator E2F and the activation of S-
phase genes, such as DHFR (Blake et al, 1989; Slansky et al, 1993)
and TS (Johnson, 1994). Consistent with this, growth inhibition by
MTX and 5-FU was increased, and DHFR and TS activities and
expression were correspondingly decreased in SaOS-2 human
sarcoma cells containing a truncated RB protein that had been
stably transfected with an RBcDNA (Li et al, 1995).
CLEAR EVIDENCE FOR A ROLE FOR THE P53
DAMAGE RESPONSE IN ACQUIRED AND
INHERENT DRUG RESISTANCE
The evidence for p53 being involved in both acquired and inherent
resistance is consistent with what we know about the role of p53
(Lane, 1992; Levine et al, 1994). p53 plays an important role in
genetic stability as a consequence ofits ability to prevent the entry
of damaged cells into the S phase of the cell cycle and thus
preventing the replication ofdamaged DNA. It is known that many
environmental insults and cancer therapies, including administra-
tion of the chemotherapeutic antimetabolites MTX, PALA and 5-
FU, increase the levels ofp53 protein expression, leading to either
arrest in the G, phase of the cell cycle or apoptosis (Kastan et al,
1991; Clarke et al, 1992; Kuerbitz et al, 1992; Livingstone et al,
1992; Yin etal, 1992; Lowe etal, 1993a,b; Di Leonardo et al, 1994;
Pickard etal, 1995). As citedabove, theG, arrestpathway probably
involves activation ofp21, which inhibitsGI cyclin-cdkcomplexes
and which in tum inhibits phosphorylation of the RB protein and
progression into the S phase of the cell cycle (Harper et al, 1993;
Xiong et al, 1993; Dulic et al, 1994). It is also likely that other
factors downstream of p53 are involved in this arrest response.
Mutations in the p53 gene eliminate these p53-dependent
responses. Mutations in the p53 gene are the commonest genetic
change in human tumours and occur in 60% oftumours overall and
75% ofcolorectal malignancies (Hollstein et al, 1991; Levine et al,
1991). The presence of a mutated or dysfunctional p53 gene
product will permit the continued replication of damaged DNA,
producing the conditions that facilitate gene amplification. This is
consistent with the observation that cells with no p53 protein (null
mutation) amplify their DNA at least a million times more readily
than cells containing the normal wild-type p53 gene product
(Livingstone et al, 1992; Yin et al, 1992). Similarly, in situations
of inherent resistance to single doses of chemotherapeutic anti-
metabolites, facilitated by the 'salvage pathways' of purine and
pyrimidine biosynthesis, mutant or dysfunctional p53 allows the
cells that eventually accumulate DNA damage (because of
restricted substrate availability) to continue to proliferate and there-
fore manifest their resistance. Loss of the p53 damage response
therefore contributes to both acquired and inherent drug resistance.
CLINICAL IMPLICATIONS
Support for the circumvention of the de novo pathways of purine
and pyrimidine biosynthesis by the salvage pathways comes from
the observation that there are sufficient levels of nucleotides and
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nucleosides in human plasma to overcome the inhibitory and cyto-
toxic effects ofthe drugs (Gordon, 1985; Sinkeler et al, 1994). The
plasma nucleotide concentrations represent a balance between the
release of nucleotides and their degradation by extracellular
nucleotidases (Boyle et al, 1989). In addition, the cytotoxic therapy
itself leads to destruction of tumour cells, which is thought to
provide high local concentrations ofnucleosides and nucleotides in
tumour patients (Fox et al, 1991).
However, few studies have dealt with the genetic factors that
might control the resistance (inherent and acquired) to DNA-
damaging agents and chemotherapeutic antimetabolites in vivo.
The recent evidence of a role for the tumour-suppressor gene p53
in mediating the response of cells to chemotherapeutic agents in
vitro (Lowe et al, 1993b; Nelson and Kastan, 1994; Pickard et al,
1995) suggests that p53 dysfunction assessed quite simply by
immunohistochemistry (Hall and Lane, 1994) might provide us
with a preliminary predictor of the likelihood of a response to
chemotherapy for individual tumours. On theoretical grounds, one
can predict that the loss of normal p53 function will be associated
with more rapidly advancing disease because of the fact that the
replication ofdamaged DNA will be associated with the induction
of additional point mutations and loss of heterozygosity (Harris
and Hollstein, 1993; Greenblatt et al, 1994). Indeed, p53 protein
expression has already been implicated as an independent prog-
nostic indicator in carcinomas of the colon, stomach, breast,
bladder and lung (NSCLC) (Dowell and Hall, 1994). The avail-
ability of immunohistochemical and polymerase chain reaction
(PCR)-based diagnostic techniques means that studies can be
performed on archival material, even from completed clinical
trials. This will provide clinicians with the opportunity both to
identify the more aggressive tumours and assess the significance of
p53 and its related pathways and pathway molecules, e.g. p21,
Gadd45, bcl2, bax, mdm2, p16 and RB (Di Leonardo et al, 1994;
Hartwell and Kastan, 1994; Miyashita et al, 1994; Reed, 1994) in
predicting chemotherapeutic and other therapeutic responses. Such
studies can address the specific and general hypotheses associated
with the progression to malignancy. For example, certain tumours
with p53 mutations might be more resistant to drug-induced apop-
tosis, while others may be more sensitive to amplification ofgenes
which might influence therapy. In the clinical situation, p53 muta-
tions have been associated with resistance to chemotherapy in
haematological malignancies (Fan et al, 1994; Hecker et al, 1994;
Wattell et al, 1994) and in a study by the authors on 59 advanced
colorectal carcinomas (Brett et al, 1996). Conversely, in testicular
tumours elevated levels of Wtp53 may contribute to their sensi-
tivity to DNA-damaging chemotherapeutic agents, which might
explain their high cure rate (Chresta et al, 1996; Chresta and
Hickman, 1996; Lutzker and Levine, 1996). Moreover, tumours
lacking RB or having functional abnormalities of this protein
might be more resistant to treatment with drugs that target DHFR
or TS. For example, cell lines from RB patients and small-cell lung
carcinomas lacking a functional RB protein are intrinsically resis-
tant to MTX. Cancer cell survival after chemotherapy will depend
on the specific cell cycle checkpoints or repair functions that have
been lost. Greater susceptibility to these agents will be observed
when the repair function is most important and greater resistance
when it is not and the cells continue to cycle or resist apoptosis. We
can predict a time when it will be possible to characterize tumours
for these functions and thereby predict their responses to specific
therapies in the clinic. Assessing the p53 and RB status oftumours
would seem an important and worthwhile first step in the process
ofidentifying subsets ofpatients with favourable and unfavourable
prognoses in response to standard treatment protocols.
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